Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Shapely vs TD Tele-Doc Weight Loss

Shapely
Graded #225

Higher grade

vs+3.6000000000000085
TD Tele-Doc Weight Loss
Graded #288

Lower grade

The verdict

Shapely takes it — 65.4/100 to 61.8/100.

Shapely grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Shapely is a GLP-1 telehealth platform founded by Dr.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueEven
45
45
Dose & formulationEven
53
53
Clinical oversightShapely +6
94
88
Labs & monitoringShapely +8
73
65
FulfillmentShapely +10
78
68
Contract termsEven
55
55
Shapely · left barTD Tele-Doc Weight Loss · right bar

The numbers

MetricShapelyTD Tele-Doc Weight Loss
WeighScore65.4/10061.8/100
GradeCC
Scorecard rank#225#288
SemaglutideNot disclosedNot disclosed
TirzepatideNot disclosedNot disclosed
Coverage4 states2 states
Brand-name accessYesYes
Oral / sublingualInjection onlyInjection only
Shapely

Graded #225 · C

Strengths

  • Founded by Dr. Justin Zaghi, MD/MBA — Harvard-trained, board-certified in internal medicine and obesity medicine, with Medical Director Ana Lisa
  • Brand-name GLP-1s (Wegovy, Ozempic, Zepbound, Mounjaro, Foundayo) covered by major PPO and Medicare at copay
  • Compounded semaglutide from $99/month with free 2-day shipping, syringes, and supplies included via 503A/503B pharmacy
  • 1:1 registered dietitian (RDN) and monthly video provider visits included in every plan; unlimited chat and app support
  • Cellular smart scale provided to qualifying patients for ongoing weight tracking throughout the program

Where it loses points

  • Currently available only in California, Florida, New York, and Texas — 46 states unserved despite announced expansion
  • Telehealth subscription ($99/mo self-pay, $49 first-month promo) is charged separately from compounded medication cost
  • Labs not included — $75 flat rate for uninsured patients; baseline bloodwork may be required before prescribing
  • No LegitScript certification found on any public page
  • Compounding pharmacy partner not named publicly; 503A/503B status claimed but specific pharmacy undisclosed
TD Tele-Doc Weight Loss

Graded #288 · C

Strengths

  • Brand Wegovy/Zepbound AND compounded sema available; prescribing based on medical history and coverage
  • 100% virtual — weekly appointments with board-certified MDs from home; no travel required
  • Remote Patient Monitoring Starter Box: biometric scale + blood pressure cuff sync to care team in real time
  • In-network with most commercial insurance plans; may cover visits and monitoring equipment
  • Physician-led by Dr. Peter Wilbanks MD (30-yr OB/GYN, VCU) and Dr. Michael Perini MD (ABIM board-certified)

Where it loses points

  • No public cash pricing; cost entirely depends on insurance coverage — not viable for uninsured patients
  • Telehealth available only in Virginia and Maryland; no national reach confirmed
  • No Medicare or Medicaid accepted; limited to commercial insurance plans only
  • No LegitScript certification found; compounded availability and specific pricing undisclosed on site
  • Tirzepatide (Zepbound/Mounjaro) availability less prominent in MD pages; semaglutide is primary focus

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard